...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan
【24h】

Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan

机译：在日本减少转移性雷戈非尼单药治疗转移性大肠癌的剂量

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib. Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined. Results: Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%). Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.
机译：背景：挽救性瑞格非尼单药治疗对转移性结直肠癌（mCRC）表现出明显的生存获益。然而，该方案的毒性导致临床上减少了剂量的雷戈非尼的使用。患者和方法：回顾性分析了接受雷戈非尼治疗的32例日本mCRC患者（中位年龄= 61岁）。结果：最佳客观缓解率为0％，稳定疾病（SD）为31％。中位无进展生存期为81天，中位总生存期为233天。在所有患者中均观察到任何等级的不良事件：17（53％）名患者遭受3或4级不良事件，包括疲劳（13％），厌食（13％），手足皮肤反应（22％）和丙氨酸升高氨基转移酶/天冬氨酸氨基转移酶（19％/ 16％）。确定了一名5级肝功能不全的患者（3％）。二十九（91％）名患者需要减少治疗剂量或延迟治疗。相对剂量强度为59％。由于疾病进展（59％）或不良事件（34％），瑞戈非尼治疗被终止。结论：尽管雷戈非尼的治疗强度有所降低，但由于严重的不良事件，在日本患者中仍取得了相当不错的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号